Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt intends to develop Episalvan as a treatment for a hereditary skin disorder called Epidermolysis Bullosa. Amryt’s earlier-stage products are focused on developing novel, next-generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases.